Search Result
Results for "
anti-leukemic
" in MedChemExpress (MCE) Product Catalog:
2
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-153274
-
|
Apoptosis
|
Cancer
|
CWI1-2 is an IGF2BP2 inhibitor that binds IGF2BP2 and inhibits its interaction with m6A-modified target transcripts, induces apoptosis and differentiation, and shows promising anti-leukemic effects .
|
-
-
- HY-N3401
-
|
Others
|
Cancer
|
Lasiodiplodin is a potent anti-leukemic macrolide can be isolated from Euphorbia splendens .
|
-
-
- HY-133900
-
|
Others
|
Cancer
|
Deoxyharringtonine is an alkaloid isolated from Cephalotaxus genus with significant anti-leukemic activity .
|
-
-
- HY-N8402
-
|
Others
|
Cancer
|
Germacrone 4,5-epoxide is a sesquiterpene that can be isolated from Curcuma cf. viridiflora. Germacrone 4,5-epoxide has excellent anti-leukemic activities .
|
-
-
- HY-153274A
-
|
Apoptosis
|
Cancer
|
CWI1-2 hydrochloride is an IGF2BP2 inhibitor that binds IGF2BP2 and inhibits its interaction with m6A-modified target transcripts, induces apoptosis and differentiation, and shows promising anti-leukemic effects .
|
-
-
- HY-134333
-
|
Apoptosis
|
Cancer
|
ICCB280 is a potent inducer of C/EBPα. ICCB280 exhibits anti-leukemic properties including terminal differentiation, proliferation arrest, and apoptosis through activation of C/EBPα and affecting its downstream targets (such as C/EBPε, G-CSFR and c-Myc) .
|
-
-
- HY-123954
-
|
Casein Kinase
CDK
Apoptosis
|
Cancer
|
Casein Kinase inhibitor A51 is a potent and orally active casein kinase 1α (CK1α) inhibitor. Casein Kinase inhibitor A51 induces leukemia cell apoptosis, and has potent anti-leukemic activities .
|
-
-
- HY-112885C
-
Nω-Hydroxy-nor-L-arginine dihydrochloride
|
Apoptosis
Arginase
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
nor-NOHA dihydrochloride is a selective and reversible arginase inhibitor. nor-NOHA dihydrochloride induces apoptosis in ARG2-expressing cells under hypoxia. nor-NOHA dihydrochloride has anti-leukemic activity. nor-NOHA dihydrochloride can used in study endothelial dysfunction, immunosuppression and metabolism .
|
-
-
- HY-112885B
-
Nω-Hydroxy-nor-L-arginine monoacetate
|
Arginase
|
Metabolic Disease
|
nor-NOHA monoacetate is a selective and reversible arginase inhibitor. nor-NOHA monoacetate induces apoptosis in ARG2-expressing cells under hypoxia. nor-NOHA monoacetate has anti-leukemic activity. nor-NOHA monoacetate can used in study of endothelial dysfunction, immunosuppression and metabolism .
|
-
-
- HY-P99412
-
OSE-127
|
Interleukin Related
|
Cancer
|
Lusvertikimab (OSE-127) is a humanized IL7R monoclonal antibody. Lusvertikimab is not internalized by target cells and prevents IL7R heterodimerization and subsequent downstream signaling. Lusvertikimab has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research .
|
-
-
- HY-135190
-
-
-
- HY-123955
-
|
Casein Kinase
CDK
Apoptosis
|
Cancer
|
Casein Kinase inhibitor A86 is a potent and orally active casein kinase 1α (CK1α) inhibitor. Casein Kinase inhibitor A86 also inhibits of CDK7 (TFIIH) and CDK9 (P-TEFb). Casein Kinase inhibitor A861 induces leukemia cell apoptosis, and has potent anti-leukemic activities .
|
-
-
- HY-N10071
-
|
Others
|
Cancer
|
Poricoic acid G is a triterpenoid that can be isolated from Poria cocos. Poricoic acid G has a significant cytotoxic effect on leukemia cells and is a potential potent anti-leukemic compound in humans .
|
-
-
- HY-112885A
-
Nω-Hydroxy-nor-L-arginine acetate
|
Arginase
Apoptosis
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
nor-NOHA acetate (Nω-Hydroxy-nor-L-arginine acetate) is a specific and reversible arginase inhibitor, induces apoptosis in ARG2-expressing cells under hypoxia but not normoxia. Anti-leukemic activity, effective in endothelial dysfunction, immunosuppression and metabolism .
|
-
-
- HY-141430
-
|
Histone Methyltransferase
|
Cancer
|
AS-85 is a potent ASH1L histone methyltransferase inhibitor (IC50=0.6 µM) with anti-leukemic activity. AS-85 strongly binds to the ASH1L SET domain, with the Kd value of 0.78 µM .
|
-
-
- HY-141429
-
|
Histone Methyltransferase
Apoptosis
|
Cancer
|
AS-99 is a first-in-class, potent and selective ASH1L histone methyltransferase inhibitor (IC50= 0.79 µM, Kd= 0.89 µM) with anti-leukemic activity. AS-99 blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo .
|
-
-
- HY-141429C
-
|
Histone Methyltransferase
Apoptosis
|
Cancer
|
AS-99 is a first-in-class, potent, and selective ASH1L histone methyltransferase inhibitor (IC50= 0.79 µM, Kd= 0.89 µM) with anti-leukemic activity. AS-99 blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo .
|
-
-
- HY-151411
-
|
Others
|
Cancer
|
RUNX1/ETO tetramerization-IN-1 is a small-molecule inhibitor of RUNX1/ETO tetramerization, exhibits anti-leukemic effect. RUNX1/ETO tetramerization-IN-1 specifically targets to NHR2 of RUNX1/ETO (EC50=0.25 μM), restores gene expression down-regulated by RUNX1/ETO. RUNX1/ETO tetramerization-IN-1 inhibits the proliferation of RUNX1/ETO-depending SKNO-1 cells, and reduces the RUNX1/ETO-related tumor growth in a mouse model .
|
-
-
- HY-141429A
-
|
Histone Methyltransferase
Apoptosis
|
Cancer
|
AS-99 TFA is a first-in-class, potent and selective ASH1L histone methyltransferase inhibitor (IC50= 0.79 µM, Kd= 0.89 µM) with anti-leukemic activity. AS-99 TFA blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo .
|
-
-
- HY-112041
-
PTC596
|
Apoptosis
|
Cancer
|
Unesbulin (PTC596) is an orally active and selective B-cell-specific Moloney murine leukemia virus integration site 1 (BMI-1) inhibitor. Unesbulin downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia (AML) cells. Unesbulin has anti-leukemic activity .
|
-
-
- HY-100423
-
KPT-8602
|
CRM1
|
Cancer
|
Eltanexor (KPT-8602) is a second-generation, highly specific and orally active exportin-1 (XPO1) inhibitor with potent anti-leukemic activity. Eltanexor (KPT-8602) inhibits XPO1-dependent nuclear export (EC50=60.9 nM) by directly targeting XPO1. Eltanexor (KPT-8602) induces Caspase-dependent apoptosis in a panel of leukemic cell lines .
|
-
-
- HY-157327
-
|
Bcr-Abl
|
Cancer
|
AKE-72 (compound 5) is a potent inhibitor of Pan-BCR-ABL. AKE-72 inhibits BCR-ABL WT, BCR-ABL T315, BCR-ABL E255K, BCR-ABL F3171, BCR-ABL H396P and BCR-ABL Q252H with IC50s of < 0.5, 9, 8.98, 3.12, < 1.0 and 3.88 nM, respectively. AKE-72 has anti-leukemic activity against K-562 cell line .
|
-
-
- HY-N7549
-
|
Others
|
Cancer
|
Dehydrobruceantin has potential antileukemic activity .
|
-
-
- HY-N3171A
-
Wikstromol
|
Apoptosis
PI3K
|
Cancer
|
(+)-Nortrachelogenin (Wikstromol), a pharmacologically ligand from from wikstroemia indica, possesses antileukemic activity .
|
-
-
- HY-17381
-
-
-
- HY-13677
-
-
-
- HY-U00095
-
NCI 329680; ZINC01574758
|
Others
|
Cancer
|
Hepsulfam (NCI 329680; ZINC01574758) is a anticancer agent that shows excellent antileukemic activity with an median IC50 of 0.91 μg/mL in a panel of different tumors.
|
-
-
- HY-N7153
-
|
Others
|
Cancer
|
10-Hydroxycanthin-6-one is an antileukemic canthin-6-one alkaloid from Brucea antidysenterica. Antitumor agent .
|
-
-
- HY-125067
-
|
Others
|
Cancer
|
Yadanzioside P is an antileukemic quassinoid glycoside. Yadanzioside P can be isolated from the seeds of Brucea javanica (L.). Yadanzioside P can be used for the research of cancer .
|
-
-
- HY-N0838
-
(-)-Cephalotaxine; ZINC19795976
|
Flavivirus
|
Infection
Cancer
|
Cephalotaxlen ((-)-Cephalotaxine) is an alkaloid that can be isolated from Cephalotaxus fortunei, with antileukemic and antiviral activities. Cephalotaxlen has anti-ZIKV (Zika virus) activity .
|
-
-
- HY-13677A
-
Mercaptopurine hydrate; 6-MP hydrate
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
6-Mercaptopurine hydrate (Mercaptopurine hydrate; 6-MP hydrate) is a purine analogue which acts as an antagonist of the endogenous purines and has been widely used as antileukemic agent and immunosuppressive agent.
|
-
-
- HY-111008
-
VF-233
|
DNA/RNA Synthesis
|
Cancer
|
Trimidox (VF-233) is a ribonucleotide reductase inhibitor with antileukemic activities. Trimidox inhibits the growth of human promyelocytic leukemia HL-60 cells with an IC50 of 35 μM .
|
-
-
- HY-111008A
-
VF-233 hydrochloride
|
DNA/RNA Synthesis
|
Cancer
|
Trimidox hydrochloride (VF-233) is a ribonucleotide reductase inhibitor with antileukemic activities. Trimidox hydrochloride inhibits the growth of human promyelocytic leukemia HL-60 cells with an IC50 of 35 μM .
|
-
-
- HY-123523
-
-
-
- HY-118144
-
|
BCRP
Src
|
Cancer
|
PD166326 is a pyridopyrimidine-type inhibitor of receptor tyrosine kinases, with IC50s of 6 nM and 8 nM for Src and Abl, respectively. PD166326 exhibits antileukemic activity .
|
-
-
- HY-102048
-
|
STAT
Apoptosis
|
Cancer
|
STAT5-IN-2 is a STAT5 inhibitor, extracted from reference 1, example 17f. STAT5-IN-2 has potent antileukemic effect .
|
-
-
- HY-117996
-
|
CRM1
Apoptosis
|
Cancer
|
KPT-251 is an orally active chromosome region maintenance 1 protein (CRM1) inhibitor. KPT-251 induces cancer cell apoptosis and shows antileukemic activity .
|
-
-
- HY-109117
-
ORY-1001
|
Histone Demethylase
|
Cancer
|
Iadademstat (ORY-1001) is a highly potent, orally active and selective LSD1 (KDM1A) inhibitor with antileukemic activity. Iadademstat can be used for relapsed or refractory acute myeloid leukemia research .
|
-
-
- HY-149334
-
-
-
- HY-115754
-
PEITC-Cys
|
DNA/RNA Synthesis
Cytochrome P450
|
Cancer
|
S-(N-PhenethylthiocarbaMoyl)-L-cysteine (PEITC-Cys), an anticarcinogenic agent, has antileukemic activity. S-(N-PhenethylthiocarbaMoyl)-L-cysteine inhibits DNA synthesis in HL60 cells . S-(N-PhenethylthiocarbaMoyl)-L-cysteine is a P450 inhibitor .
|
-
-
- HY-147717
-
|
CDK
|
Cancer
|
CDK8-IN-7 (compound 12) is a potent and selective cyclin-dependent kinase 8 (CDK8) inhibitor with an Kd of 3.5 nM. CDK8-IN-7 shows cytotoxicity for MOLM-13, OCI-AML3, MV4-11, NRK and H9c2 cells with IC50s of 5.9, 4.8, 5.4, 16.2, 12.5-25 µM, respectively. CDK8-IN-7 has the potential for the research of AML-cancer .
|
-
-
- HY-147716
-
|
CDK
|
Cancer
|
CDK8-IN-6 (compound 9) is a potent cyclin-dependent kinase 8 (CDK8) inhibitor with an Kd of 13 nM. CDK8-IN-6 shows cytotoxicity for MOLM-13, OCI-AML3, MV4-11, NRK and H9c2 cells with IC50s of 11.2, 7.5, 8.6, 20.5, 12.5-25 µM, respectively. CDK8-IN-6 has the potential for the research of AML-cancer .
|
-
-
- HY-13677S
-
-
-
- HY-122295
-
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
Dehydroleucodine is a sesquiterpene lactone isolated from Artemisia douglasiana. Dehydroleucodine is a mast cell stabilizer that inhibits tmast cell degranulation induced by compound 48/80. Dehydroleucodine inudces cells apoptosis, and has gastric ulcer inhibition and antileukemic effects .
|
-
-
- HY-13677S1
-
Mercaptopurine-13C2,15N; 6-MP-13C2,15N
|
Nucleoside Antimetabolite/Analog
Autophagy
Endogenous Metabolite
|
Cancer
|
6-Mercaptopurine- 13C2, 15N is the 13C- and 15N-labeled 6-Mercaptopurine. 6-Mercaptopurine is a purine analogue which acts as an antagonist of the endogenous purines and has been widely used as antileukemic agent and immunosuppressive agent.
|
-
-
- HY-15003
-
|
FLT3
Apoptosis
|
Cancer
|
ATH686 is a potent, selective and ATP-competitive FLT3 inhibitor. ATH686 target mutant FLT3 protein kinase activity and inhibit the proliferation of cells harboring FLT3 mutants via induction of apoptosis and cell cycle inhibition. ATH686 has antileukemic effects .
|
-
-
- HY-17381A
-
4-Demethoxydaunorubicin
|
Topoisomerase
Bacterial
Fungal
Autophagy
c-Myc
DNA/RNA Synthesis
Antibiotic
|
Infection
Cancer
|
Idarubicin is an orally active and potent anthracycline antileukemic agent. Idarubicin inhibits the topoisomerase II interfering with the replication of DNA and RNA transcription. Idarubicin shows induction of DNA damage. Idarubicin inhibits DNA synthesis and of c-myc expression. Idarubicin inhibits the growth of bacteria and yeasts .
|
-
-
- HY-P2970
-
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
Stem bromelain (EC 3.4.22.32) is a cysteine proteinase, isolated from pineapple (Ananas comosus) stem. Stem bromelain is a major bromelain, which exhibits various fibrinolytic, antiedematous, antithrombotic, and anti-inflammatory activities. Stem bromelain has in vivo antitumoral and antileukemic activity, as well as antimetastatic action .
|
-
-
- HY-135231
-
NL-1
1 Publications Verification
|
Mitochondrial Metabolism
Autophagy
|
Cancer
|
NL-1 is a mitoNEET inhibitor with antileukemic effect. NL-1 inhibits REH and REH/Ara-C cells growth with IC50s of 47.35 µM and 56.26 µM, respectively. NL-1-mediated death in leukemic cells requires the activation of the autophagic pathway .
|
-
-
- HY-151897
-
|
HDAC
|
Cancer
|
HDAC-IN-49 is a potent unselective HDAC (HDAC) inhibitor with IC50s of 13 nM, 14 nM, 21 nM, 1880 nM, and 10 nM for HDAC1, HDAC2, HDAC3, HDAC4, and HDAC6. HDAC-IN-49 demonstrates prominent antileukemic activity with low cytotoxic activity toward healthy cells .
|
-
- HY-155390
-
|
Caspase
Apoptosis
|
Cancer
|
Caspase-3 activator 3 (compound 2h) induces apoptosis in HL-60 and K562 cells via significant caspase 3 activation. Caspase-3 activator 3 shows antileukemic acticity against HL-60 and K562 cells, with IC50 values of 42.89 and 33.61 μM, respectively .
|
-
- HY-134978B
-
|
SHMT
|
Cancer
|
(-)SHIN2 is the isomer of (+)SHIN2 (HY-134978A). (+)SHIN2 is an inhibitor of serine hydroxymethyltransferase (SHMT) with antileukemic effect. (+)SHIN2 synergisty with and Methotrexate (HY-14519) in vivo xenotransplantation models . (-)SHIN2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-143278
-
|
Topoisomerase
FLT3
Apoptosis
|
Cancer
|
FLT3-IN-13 (compound 20) is a potent and effective antileukemic topoisomerase II and FLT3 dual inhibitor with IC50 values of 2.26 μM and 2.26 μM, respectively. FLT3-IN-13 arrests cell cycle at G2/M phase and induce apoptosis. FLT3-IN-13 has anticytotoxic activity, particularly against leukemia .
|
-
- HY-12707
-
-
- HY-12707A
-
-
- HY-12707C
-
-
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99412
-
OSE-127
|
Interleukin Related
|
Cancer
|
Lusvertikimab (OSE-127) is a humanized IL7R monoclonal antibody. Lusvertikimab is not internalized by target cells and prevents IL7R heterodimerization and subsequent downstream signaling. Lusvertikimab has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-13677S1
-
|
6-Mercaptopurine- 13C2, 15N is the 13C- and 15N-labeled 6-Mercaptopurine. 6-Mercaptopurine is a purine analogue which acts as an antagonist of the endogenous purines and has been widely used as antileukemic agent and immunosuppressive agent.
|
-
-
- HY-13677S
-
|
6-Mercaptopurine-d2 is the deuterium labeled 6-Mercaptopurine. 6-Mercaptopurine is a purine analogue which acts as an antagonist of the endogenous purines and has been widely used as antileukemic agent and immunosuppressive agent[1][2].
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: